Duvelisib
PI3K inhibitor / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Duvelisib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed.[6] It is taken by mouth.[6] It is a PI3 kinase inhibitor.[7]
Quick Facts Clinical data, Pronunciation ...
Clinical data | |
---|---|
Pronunciation | doo-VE-li-sib |
Trade names | Copiktra |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618056 |
License data | |
Routes of administration | By mouth (capsules) |
Drug class | PI3-Kinase inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | mainly metabolized by CYP3A4[2] |
Onset of action | 1-2 hours after initial administration |
Elimination half-life | 5.2 to 10.9 hours |
Excretion | Feces (79%), urine (14%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.245.560 |
Chemical and physical data | |
Formula | C22H17ClN6O |
Molar mass | 416.87 g·mol−1 |
3D model (JSmol) | |
|
Close
Common side effects include diarrhea, low white blood cells, rash, feeling tired, fever, and muscle pains.[6] Other serious side effects include inflammation of the lungs and infections.[6] It is a dual inhibitor of PI3Kδ and PI3Kγ.[8]